BioCentury
ARTICLE | Clinical News

Bisnorcymserine: Phase I started

July 30, 2012 7:00 AM UTC

QR Pharma began a double-blind Phase I trial to evaluate single ascending-doses of 20, 40, 80, 160, 380, 490 and 600 mg bisnorcymserine in up to 56 healthy elderly volunteers. The company has exclusiv...